Medicine and Dentistry
Nivolumab
100%
Childbirth
100%
Ipilimumab
66%
Blood Clot Lysis
50%
Apoplexy
50%
Magnetic Resonance Imaging
50%
Thrombectomy
50%
Sequela
50%
Oncology
16%
Cytotoxic T Lymphocyte Antigen 4 Antibody
16%
Biopharmaceuticals
16%
Anticarcinogen
16%
T Cell
16%
Immunoglobulin
16%
CTLA-4
16%
Cancer Immunotherapy
16%
6 Diazo 5 Oxonorleucine
16%
Clinical Trial
16%
Pharmacology, Toxicology and Pharmaceutical Science
Nivolumab
100%
Ipilimumab
66%
Pear
33%
Cytotoxic T Lymphocyte Antigen 4
16%
Cytotoxic T Lymphocyte Antigen 4 Antibody
16%
Mouse
16%
Neoplasm
16%
Immunotherapy
16%
Immunoglobulin
16%
Clinical Trial
16%
6 Diazo 5 Oxonorleucine
16%
Anticarcinogen
16%